Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2016-01-31 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于《中国证监会行政许可项目审查反馈意见通知书》之反馈意见回复的补充修订的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Shandong Ruikang Pharmaceutical Co., Ltd. regarding the supplementary revision of their response to feedback from the China Securities Regulatory Commission (CSRC) on their non-public stock issuance application. It discusses adjustments to the issuance price and quantity, submission of revised materials, and the need for approval from the shareholders' meeting and CSRC. The document is short (926 characters) and primarily serves as an announcement of regulatory feedback and procedural updates related to capital raising activities. It does not contain financial statements or detailed financial data, nor is it a full report or transcript. The content aligns with updates on company fundraising and capital structure changes, fitting the Capital/Financing Update (CAP) category rather than a full report or regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2016-01-31 Chinese
关于实际控制人参与认购非公开发行股票构成关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a non-public issuance of A shares by Shandong Ruikang Pharmaceutical Co., Ltd., involving the actual controller subscribing to the shares, which constitutes a related party transaction. It details the pricing, subscription agreements, approvals by the board and shareholders, and regulatory compliance with the China Securities Regulatory Commission. The document is focused on capital raising through a non-public share issuance and related party transactions, including subscription details and approvals. It is not a full financial report, earnings release, or management discussion, but rather an update on financing activities and related transactions. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and content support this classification with high confidence.
2016-01-31 Chinese
国金证券股份有限公司关于公司非公开发行股票申请文件反馈意见的回复（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed response to feedback from the China Securities Regulatory Commission regarding a non-public stock issuance application by Shandong Ruikang Pharmaceutical Co., Ltd. It includes extensive financial data, project investment details, and compliance with regulatory requirements for the issuance. The content focuses on the non-public issuance of shares, fundraising projects, and regulatory compliance, which aligns with capital raising and financing activities. There is no indication that this is an annual report, earnings release, or other types of filings. The document is substantive and lengthy (15,000 characters), containing detailed financial and project information, not merely an announcement or certification. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2016-01-31 Chinese
2016年第一次临时股东大会的律师见证法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2016 first extraordinary general meeting (EGM) of Shandong Ruikang Pharmaceutical Co., Ltd. It details the legal verification of the convening, attendance, agenda, voting procedures, and results of the EGM. The document does not contain financial statements or management discussion but focuses on the legal validation of the shareholder meeting and its resolutions. This type of document is typically classified as a Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes and legal compliance of a shareholder meeting. The document length is about 4708 characters, which is consistent with a detailed legal opinion on voting results rather than a full annual or interim report or a simple announcement. Therefore, the appropriate classification is DVA with high confidence.
2016-01-27 Chinese
2016年第一次临时股东大会决议的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the 2016 first extraordinary general meeting of shareholders of Shandong Ruikang Pharmaceutical Co., Ltd. It includes details about the meeting notice, attendance, voting results on various proposals, and legal opinion on the meeting's legality. The document does not contain financial statements or detailed financial analysis but reports the official voting results of the shareholder meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1901 characters), consistent with a voting results announcement rather than a full report.
2016-01-27 Chinese
关于实际控制人进行股票质押式回购交易的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement regarding a stock pledge repurchase transaction by the company's actual controller. It details the number of shares pledged, the parties involved, and the terms of the pledge. There is no financial report, earnings data, or management discussion. The content fits the description of a Transaction in Own Shares (POS) filing, as it involves share pledging and related transactions by a significant shareholder. The document length is short and focused on this specific transaction, not a report or announcement of a report publication.
2016-01-22 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.